BioCentury
ARTICLE | Clinical News

BM32: Phase IIb data

February 9, 2015 8:00 AM UTC

Data from 141 evaluable patients with grass pollen allergy in a double-blind, European Phase IIb trial showed that subcutaneous BM32 improved the mean daily combined symptom and medication score, the ...